Pharma News

Genome sequencing of thousands of SARS-CoV-2 samples shows that surges of COVID-19 cases are driven by the appearance of new coronavirus variants, according to new research from the School of Veterinary Medicine at the University of California, Davis, published April 1 in Scientific Reports.

UConn researcher Paulo Verardi, associate professor of pathobiology and veterinary science in the College of Agriculture, Health and Natural Resources, has demonstrated the success of a vaccine against Zika virus and recently published his findings in Scientific Reports, a Nature Research publication.

Alembic Pharmaceuticals Limited announced that its joint venture Aleor Dermaceuticals Limited (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram, of Taro Pharmaceuticals U.S.A. Inc.

Efforts to find a treatment for mitochondrial disorders is set to get a major boost with a team of researchers at the Department of Biotechnology’s National Institute of Immunology (DBT-NII) figuring out a way to tackle autosomal dominant progressive external ophthalmoplegia (adPEO), which is a widely prevalent mitochondrial disorder.

Replacing regular common salt consumed by hypertensive patients in rural areas with a salt substitute can have a significant impact in terms of lowering their blood pressure, a new study by The George Institute for Global Health (GIGH) has revealed.

New research published this month in Frontiers in Medicine (Gastroenterology) reveals that individuals with both obesity and severe fatty liver are five times more likely to require hospitalization for the illness. The non-invasive liver imaging technology — Perspectum’s LiverMultiScan — was used to gather MRI scans for the study.

Germany and Canada have restricted the use of the AstraZeneca vaccine to people over 60 and 55 respectively, due to fear that it can lead to deadly blood clots.

Health Minister of Germany, Jens Spahn and state officials agreed unanimously on Tuesday to only give the vaccine to people aged 60 or older unless they belong to a high-risk category for serious illness from COVID-19 and have agreed with their doctor to take the vaccine despite the small risk of a serious side-effect.

ICMR reported that Covishield and Covaxin vaccines are effective against the UK and the Brazilian variants of coronavirus, and several laboratories are involved in work against South African strain. Addressing a weekly press conference of the Union health ministry, ICMR Director-General Balram Bhargava also said of 11,064 genome samples sequenced in the country, the UK variant of the virus was detected in 807, the South African variant in 47 and the Brazilian variant was found in one.

Takeda announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the prevention of dengue due to any dengue virus serotype in individuals ages four to 60. Takeda intends to submit regulatory filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand during 2021.